Cotiga Delia, Ehlert Frederick, Sherrid Mark
Division of Cardiovascular and Thoracic Surgery, St. Luke's/Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Anadolu Kardiyol Derg. 2006 Dec;6 Suppl 2:55-60.
Sudden cardiac death is the most devastating complication of hypertrophic cardiomyopathy. Since HCM may present at young age, and since the risk period for sudden arrhythmic death may be long, decision-making in HCM patients may be difficult, and have lifelong implications. Community based studies show a sudden death mortality of approximately 1%/year. Certain patients can be identified by their clinical characteristics, and through testing, to have higher annual risk, as high as 4-5%/year. Risk factors sudden cardiac death include: family history of HCM and sudden death, recurrent syncope, ventricular tachycardia, as detected by Holter monitoring or exercise testing, subnormal (<20 mmHg) increase in systolic blood pressure on maximal exercise testing and lastly marked (especially >30 mm) left ventricular hypertrophy. The implantable defibrillator has been shown to avert sudden death in selected HCM patients deemed to be at high risk.
心脏性猝死是肥厚型心肌病最具毁灭性的并发症。由于肥厚型心肌病可能在年轻时发病,且心律失常性猝死的风险期可能很长,因此肥厚型心肌病患者的决策可能很困难,且会产生终身影响。基于社区的研究表明,心脏性猝死的死亡率约为每年1%。某些患者可通过其临床特征以及检测被确定为年风险较高,高达每年4 - 5%。心脏性猝死的危险因素包括:肥厚型心肌病家族史和猝死家族史、反复晕厥、动态心电图监测或运动试验检测到的室性心动过速、最大运动试验时收缩压升高不足(<20 mmHg),以及最后显著的(尤其是>30 mm)左心室肥厚。已证明植入式心脏除颤器可避免选定的被认为高风险的肥厚型心肌病患者发生心脏性猝死。